Weiming Xia, PhD
Professor, Pharmacology, Physiology & Biophysics
Biography
Dr. Xia completed his graduate studies at the University of Texas Medical School at Houston where he earned his MS and PhD degrees (Biochemistry and Molecular Biology). He completed his postdoctoral training in Alzheimer’s disease (AD) at Brigham and Women’s Hospital, Harvard Medical School. In 1999 he became Assistant Professor of Neurology at Harvard Medical School and established a NIH-funded research lab to study AD. In 2012 he joined Department of Veterans Affairs Bedford VA Medical Center, and he leads an independent lab to explore molecular mechanism and biomarkers for AD.
Dr. Xia’s research interests involve target identification, characterization, validation and early stage drug development, with exploration of clinical biomarkers for AD. He has established multiple platforms to quantify pathological proteins like amyloid ß protein (Aß), Tau, neuroinflammatory factors, and related biomarkers. He also develops Mass Spectrometry-based analytic approaches to explore biomarkers for AD and other central nervous system disorders.
Other Positions
- Bedford VA - Edith Nourse Rogers Memorial VA Hosp
Education
- University of Texas Health Science Center at Houston, PhD
- University of Texas Health Science Center at Houston, MS
- Fudan University, BS
Publications
- Published on 3/18/2023
Morin PJ, Zhang Q, Xia W, Miller D, Querfurth H, Tahami Monfared AA. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer's Disease. Neurol Ther. 2023 Jun; 12(3):721-726. PMID: 36933140.
Read at: PubMed - Published on 1/20/2023
Kirsch D, Shah A, Dixon E, Kelley H, Cherry JD, Xia W, Daley S, Aytan N, Cormier K, Kubilus C, Mathias R, Alvarez VE, Huber BR, McKee AC, Stein TD. Vascular injury is associated with repetitive head impacts and tau pathology in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2023 Jan 20; 82(2):127-139. PMID: 36617181.
Read at: PubMed - Published on 12/31/2022
Prasad M, Xu J, Agranat JS, Xia W, Daley S, Ness S, Chen X, Siegel NH, Stein TD, Chung J, Subramanian ML. Upregulation of Neuroinflammatory Protein Biomarkers in Acute Rhegmatogenous Retinal Detachments. Life (Basel). 2022 Dec 31; 13(1). PMID: 36676067.
Read at: PubMed - Published on 7/1/2022
Morin P, Li M, Wang Y, Aguilar BJ, Berlowitz D, Tahami Monfared AA, Irizarry M, Zhang Q, Xia W. Clinical Staging of Alzheimer's Disease: Concordance of Subjective and Objective Assessments in the Veteran's Affairs Healthcare System. Neurol Ther. 2022 Sep; 11(3):1341-1352. PMID: 35778542.
Read at: PubMed - Published on 2/9/2022
Panitch R, Hu J, Xia W, Bennett DA, Stein TD, Farrer LA, Jun GR. Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease. Alzheimers Res Ther. 2022 02 09; 14(1):30. PMID: 35139885.
Read at: PubMed - Published on 2/9/2022
Turk KW, Geada A, Alvarez VE, Xia W, Cherry JD, Nicks R, Meng G, Daley S, Tripodis Y, Huber BR, Budson AE, Dwyer B, Kowall NW, Cantu RC, Goldstein LE, Katz DI, Stern RA, Alosco ML, Mez J, McKee AC, Stein TD. A comparison between tau and amyloid-ß cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease. Alzheimers Res Ther. 2022 02 09; 14(1):28. PMID: 35139894.
Read at: PubMed - Published on 2/9/2022
Jun GR, You Y, Zhu C, Meng G, Chung J, Panitch R, Hu J, Xia W, Bennett DA, Foroud TM, Wang LS, Haines JL, Mayeux R, Pericak-Vance MA, Schellenberg GD, Au R, Lunetta KL, Ikezu T, Stein TD, Farrer LA. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ?2 for Alzheimer's disease. Alzheimers Dement. 2022 Nov; 18(11):2042-2054. PMID: 35142023.
Read at: PubMed - Published on 12/2/2021
Stathas S, Alvarez VE, Xia W, Nicks R, Meng G, Daley S, Pothast M, Shah A, Kelley H, Esnault C, McCormack R, Dixon E, Fishbein L, Cherry JD, Huber BR, Tripodis Y, Alosco ML, Mez J, McKee AC, Stein TD. Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease. Alzheimers Dement. 2022 Aug; 18(8):1511-1522. PMID: 34854540.
Read at: PubMed - Published on 9/3/2021
Panitch R, Hu J, Chung J, Zhu C, Meng G, Xia W, Bennett DA, Lunetta KL, Ikezu T, Au R, Stein TD, Farrer LA, Jun GR. Integrative brain transcriptome analysis links complement component 4 and HSPA2 to the APOE e2 protective effect in Alzheimer disease. Mol Psychiatry. 2021 10; 26(10):6054-6064. PMID: 34480088.
Read at: PubMed - Published on 9/1/2021
Ratner MH, Downing SS, Guo O, Odamah KE, Stewart TM, Kumaresan V, Robitsek RJ, Xia W, Farb DH. Prodromal dysfunction of a5GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer's disease. Heliyon. 2021 Sep; 7(9):e07895. PMID: 34568591.
Read at: PubMed
View 113 more publications: View full profile at BUMC